In a research report issued today, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Bio Blast Pharma (NASDAQ:ORPN) with a price target …
In a research report issued today, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Bio Blast Pharma (NASDAQ:ORPN) with a $15 …
